Molecular Docking analysis of the interaction between
metformin/glimepiride combination and organic cation transporter in Diabetic patients
1
Chemistry, Department of Chemistry, College of Science for Women, University of Baghdad, Iraq
Publication date: 2026-06-30
Corresponding author
Ekhlass M. Taha
Chemistry, Department of Chemistry, College of Science for Women, University of Baghdad, Al-Jadriya, 10001, Baghdad, Iraq
Chemistry, Department of Chemistry, College of Science for Women, University of Baghdad, Al-Jadriya, 10001, Baghdad, Iraq
Wiadomości Lekarskie 2026;(6):1223-1230
KEYWORDS
TOPICS
ABSTRACT
Aim:
This study aimed to evaluate the interaction of glimepiride/metformin with organic cation transporter protein-1 (OCT-1) using molecular docking technology, as well as to determine the drug's effect on serum OCT-1 levels in patients compared to healthy individuals. This may contribute to understanding the efficacy of this treatment in controlling blood glucose levels.
Material and methods:
Molecular docking technology was used to determine the interaction of the glimepiride/metformin combination with organic cation transporter 1 (OCT-1). The study included 50 women: 26 with type 2 diabetes and 24 healthy women as a control group. ELISA was used to determine the levels of organic cations in the participants' serum.
Results:
The results showed a high binding energy of -10.2 kcal/mol between the glimepiride/metformin combination and the OCT-1 protein, indicating the drug's efficacy in treating diabetes. These results confirm the findings of the clinical trial on OCT-1, which showed that the protein level in patients was (511.6 ± 120.3), similar to the concentration in the control group (558.8 ± 39.2), indicating that most of the drug had entered the cells.
Conclusions:
The results suggest that the glimepiride/metformin combination is a recommended treatment option for lowering blood glucose levels and treating type 2 diabetes.
This study aimed to evaluate the interaction of glimepiride/metformin with organic cation transporter protein-1 (OCT-1) using molecular docking technology, as well as to determine the drug's effect on serum OCT-1 levels in patients compared to healthy individuals. This may contribute to understanding the efficacy of this treatment in controlling blood glucose levels.
Material and methods:
Molecular docking technology was used to determine the interaction of the glimepiride/metformin combination with organic cation transporter 1 (OCT-1). The study included 50 women: 26 with type 2 diabetes and 24 healthy women as a control group. ELISA was used to determine the levels of organic cations in the participants' serum.
Results:
The results showed a high binding energy of -10.2 kcal/mol between the glimepiride/metformin combination and the OCT-1 protein, indicating the drug's efficacy in treating diabetes. These results confirm the findings of the clinical trial on OCT-1, which showed that the protein level in patients was (511.6 ± 120.3), similar to the concentration in the control group (558.8 ± 39.2), indicating that most of the drug had entered the cells.
Conclusions:
The results suggest that the glimepiride/metformin combination is a recommended treatment option for lowering blood glucose levels and treating type 2 diabetes.
Share
RELATED ARTICLE
| eISSN: | 2719-342X |
| ISSN: | 0043-5147 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
